Nordic Bioscience's prospects for a stock market debut are now tied to the outcome of clinical trials for a potential weight-loss therapy, with results expected this autumn.
The Copenhagen-based biotech firm is positioning itself as a contender in the rapidly expanding obesity treatment market, but its ability to attract public investors will largely depend on the efficacy data from its ongoing studies.
The timing of the trial readout is critical for the company's fundraising strategy.
A positive outcome could provide the validation needed to proceed with an initial public offering, while negative results may force a delay or a pivot in strategy.
The obesity drug sector has seen intense competition and high valuations, driven by the success of Novo Nordisk and Eli Lilly, making the bar for new entrants exceptionally high.
Nordic Bioscience has been developing its pipeline with the aim of offering a differentiated approach to weight management.